Literature DB >> 21475371

Genetic determinants of prostate cancer: a review.

Milan Kral1, Vlasta Rosinska, Vladimir Student, Michal Grepl, Martin Hrabec, Jan Bouchal.   

Abstract

BACKGROUND: In prostate cancer, early detection and appropriate treatment remain key approaches. But given the constantly increasing incidence, prostate cancer ethiopathogenetic determinants are a current focus of attention. Although the development of this cancer is influenced by both environmental and genetic factors which are as yet ill-defined, genetic studies have revealed gene abnormalities which may be specifically associated with the risk of prostate cancer: changes in genes for the androgen receptor, RNAseL, ELAC2, MSR1, BRCA 1 and 2, HPCX, KLF6, HPC20 and fusion genes, e.g. TMPRSS2-ERG). Despite differing research results from molecular biological studies, these techniques can assist in earlier diagnosis enabling timely initiation of treatment.
METHODS: Methods and literature: MEDLINE search was performed to collect both original and review articles addressing prostate cancer and genetic risk factors using key words genetics, prostate cancer and risk.
CONCLUSIONS: A number of potential genetic risk factors/markers has been identified which may in near future contribute to earlier diagnosis of prostate cancer so that earlier treatment can be started. Despite many promising data we have found differing results and therefore we suppose further research should be conducted to achieve more precise conclusion. This review focuses on current knowledge of the genetic factors affecting the development of prostate cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21475371     DOI: 10.5507/bp.155.2011.001

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  7 in total

Review 1.  Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.

Authors:  M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

2.  Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

Authors:  Taduru L Sreenath; Albert Dobi; Gyorgy Petrovics; Shiv Srivastava
Journal:  J Carcinog       Date:  2011-12-31

3.  Can glycoprofiling be helpful in detecting prostate cancer?

Authors:  Štefan Belický; Jan Tkac
Journal:  Chem Zvesti       Date:  2014-11-28       Impact factor: 2.097

Review 4.  Oncolytic adenovirus-mediated therapy for prostate cancer.

Authors:  Katrina Sweeney; Gunnel Halldén
Journal:  Oncolytic Virother       Date:  2016-07-14

5.  Polymorphism of glutathione S-transferase in the population of Polish patients with carcinoma of the prostate.

Authors:  Joanna M Drozdz-Afelt; Beata Koim-Puchowska; Grzegorz Klosowski; Piotr Kaminski
Journal:  Environ Sci Pollut Res Int       Date:  2020-03-24       Impact factor: 4.223

6.  Identification of Potential Genes for Benign Prostatic Hyperplasia and Prostate Cancer Susceptibility in Four X-chromosome Regions with High Frequency of Microvariant Alleles.

Authors:  Mohammed H Albujja; Safia A Messaudi; Ramachandran Vasudevan; Saleh Al Ghamdi; Pei Pei Chong; Khairul Asri Ghani; Yazan Ranneh; Mohammed Alaidarous; Patimah Ismail
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01

Review 7.  Overview of research on fusion genes in prostate cancer.

Authors:  Chunjiao Song; Huan Chen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.